Principal Investigator
Carl Landgren
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20230685
Clinical Trial Summary
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION
WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN
COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED
REFRACTORY MULTIPLE MYELOMA
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Myeloma
Contact Information
Phone Number
305-243-2647